Evidence map›Paper›PMID 39836837›Full record

ArticleBiomedica : revista del Instituto Nacional de Salud2024

Clinical and genetic description of patients with chronic granulomatous disease in a pediatric hospital

Xareni Berriozábal-Villarruel, Guadalupe Fernanda Godínez-Zamora, Patricia Baeza-Capetillo, Uriel Pérez-Blanco, Sara Elva Espinosa-Padilla, Jesús Aguirre-Hernández, Lizbeth Blancas-Galicia, Omar Josué Saucedo-Ramírez

Abstract readCase ReportsEnglish Abstract
In one paragraph

Article in Biomedica : revista del Instituto Nacional de Salud, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xareni Berriozábal-VillarruelDepartamento de Alergología e Inmunología Clínica, Hospital Infantil de México Federico Gómez, Ciudad de México, Méxic.ORCID 0009-0004-3336-0149
Guadalupe Fernanda Godínez-ZamoraLaboratorio de Genómica, Genética y Bioinformática, Hospital Infantil de México, Federico Gómez, Ciudad de México, México.ORCID 0009-0007-1925-0041
Patricia Baeza-CapetilloLaboratorio de Genómica, Genética y Bioinformática, Hospital Infantil de México, Federico Gómez, Ciudad de México, México.
Uriel Pérez-BlancoLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0009-0000-2156-2166
Sara Elva Espinosa-PadillaLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0000-0003-4859-3151
Jesús Aguirre-Hernándezaboratorio de Genómica, Genética y Bioinformática, Hospital Infantil de México, Federico Gómez, Ciudad de México, México.ORCID 0000-0002-2715-6422
Lizbeth Blancas-GaliciaLaboratorio de Inmunodeficiencias, Instituto Nacional de Pediatría, Ciudad de México, México.ORCID 0000-0002-3861-8864
Omar Josué Saucedo-RamírezDepartamento de Alergología e Inmunología Clínica, Hospital Infantil de México Federico Gómez, Ciudad de México, México.ORCID 0000-0001-9193-0091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic granulomatous disease is a congenital immune disorder characterized by increased susceptibility to fungal and bacterial infections and dysregulated inflammation. It is caused by defects in the NADPH oxidase and EROS protein. Objective: To characterize clinically and genetically four patients with chronic granulomatous disease at the Hospital Infantil de México Federico Gómez. Materials and methods: Patients diagnosed with chronic granulomatous disease by the dihydrorhodamine oxidase technique were molecularly and genetically characterized by measuring NADPH oxidase subunit expression and exome sequencing and analysis. The different clinical variables were obtained from clinical files, and each case was described. Results: We described four male patients with chronic granulomatous disease: two with pathogenic variants in CYBB, one with CYBB and adjacent genes deleted, and one without p47phox expression. Mothers of the three patients with mutated CYBB were carriers. All three cases with CYBB had severe and recurrent infections in addition to Calmette-Guérin bacillus infection as the initial manifestation. The autosomal recessive case of p47phox deficiency had the mildest clinical presentation. Deleting CYBB and several contiguous genes was associated with a poor prognosis. None of the patients received hematopoietic stem cell transplantation. Conclusions: Chronic granulomatous disease, secondary to pathogenic variants in CYBB was the most common in these Mexican patients. The carrier mothers should be followed clinically because of the potential risk of inflammatory, autoimmune, and infectious manifestations. One of the first manifestations was Calmette-Guérin bacillus infection, and in countries such as Mexico, where this vaccine is administered, cases with any type of adverse reaction should be evaluated to rule out chronic granulomatous disease.

Indexed as

Granulomatous Disease, ChronicNADPH Oxidase 2ChildChild, PreschoolFemaleHospitals, PediatricHumansInfantMaleMexicoMutationNADPH OxidasesCYBB protein, humanNADPH Oxidase 2NADPH Oxidasesneutrophil cytosolic factor 1BCG vaccinechronicfollow-up studiesgranulomatous diseaseNADPH oxidase 2

Identifiers

PMID39836837
PMCPMC12014213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.